



Docket No.: 240156US0DIV

COMMISSIONER FOR PATENTS
ALEXANDRIA, VIRGINIA 22313



ATTORNEYS AT LAW

RE: Application Serial No.: 10/620,462
Applicants: Catherine ROUGEOT, et al.
Filing Date: July 17, 2003
For: THERAPEUTIC USE OF THE SMR1 PROTEIN AND
ACTIVE DERIVATIVES THEREOF
Group Art Unit: 1643
Examiner: K. CANELLA

SIR:


Attached hereto for filing are the following papers:

Amendment and Request for Reconsideration

Our check in the amount of \$0.00 is attached covering any required fees. In the event any variance exists between the amount enclosed and the Patent Office charges for filing the above-noted documents, including any fees required under 37 C.F.R. 1.136 for any necessary Extension of Time to make the filing of the attached documents timely, please charge or credit the difference to our Deposit Account No. 15-0030. Further, if these papers are not considered timely filed, then a petition is hereby made under 37 C.F.R. 1.136 for the necessary extension of time. A duplicate copy of this sheet is enclosed.

Respectfully submitted,

OBLON, SPIVAK, McCLELLAND,
MAIER & NEUSTADT, P.C.
Norman F. Oblon



Thomas M. Cunningham, Ph.D.

Registration No. 45,394

Customer Number

22850

(703) 413-3000 (phone)
(703) 413-2220 (fax)



DOCKET NO.: 240156US0DIV

IN THE UNITED STATES PATENT & TRADEMARK OFFICE

IN RE APPLICATION OF :
CATHERINE ROUGEOT, ET AL. : GROUP ART UNIT: 1643
SERIAL NO: 10/620,462 :
FILED: JULY 17, 2003 : EXAMINER: K. CANELLA
FOR: THERAPEUTIC USE OF THE SMR1 :
PROTEIN AND ACTIVE
DERIVATIVES THEREOF

AMENDMENT & REQUEST FOR RECONSIDERATION

COMMISSIONER FOR PATENTS,
ALEXANDRIA, VIRGINIA 22313

SIR:

In response to the Notice of January 25, 2007 and the Official Action mailed June 29, 2006, please amend this application as shown below. This Amendment is identical to the Amendment filed October 27, 2006, except that the underlining has been removed from the number "65" in Claim 77.

Amendments to the Claims are reflected in the listing of claims which begins on page 2 of this paper.

Remarks begin on page 8 of this paper.